News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

PharmaJet Release: NIH Clinical Trial For Needle-Free Zika Vaccine Showing Promise

11/29/2016 10:39:15 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

GOLDEN, Colo., Nov. 29, 2016 /PRNewswire/ -- PharmaJet, the maker of innovative, needle-free injection technology, was featured on a CBS 60 Minutes segment concerning the National Institutes of Health DNA vaccine clinical trial for the Zika virus.  

There are now more than 30,000 diagnosed Zika cases in every state but Alaska, with most of those in the U.S. territory of Puerto Rico.  Because it is now known that Zika can be transmitted through mosquitoes, blood and sex, that number is expected to rise.

The vaccine has shown in initial trials that it generates the expected immune response to fight the Zika virus.  The plan is to now test the vaccine in thousands of volunteers living in Zika-infected areas like Puerto Rico.  "If the vaccine protects people there," Dr. Anthony Fauci, head of infectious diseases at the NIH told the 60 Minutes reporter, "it could be ready for distribution by early 2018."

"We are encouraged by the positive results of the Zika vaccine trial. The PharmaJet needle-free injection device offers a safe, fast and easy-to-use method to deliver the vaccine," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet Inc.

For more information on PharmaJet's needle-free technology, please visit

Refer to Instructions for Use to ensure safe injections and to review risks.

About PharmaJet

Based in Golden, Colorado, PharmaJet's mission is worldwide acceptance of PharmaJet needle-free devices as a standard of care in the vaccine delivery market.  PharmaJet's devices are also integral in the development of multiple novel pharmaceuticals.  The innovative Stratis® device has U.S. FDA 510(k) marketing clearance, CE Mark and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously.  In August 2014, the PharmaJet Stratis® device was cleared for delivery of an influenza vaccine to deliver needle-free flu shots.  The Tropis® device for intradermal injections received authorization to apply the CE Mark in May 2016.  The PharmaJet Needle-free devices are safe, fast and easy-to-use.  They eliminate needlestick injuries, needle reuse and cross contamination, and help reduce sharps waste disposal.  For more information, visit

Jackie Daane

To view the original version on PR Newswire, visit:

SOURCE PharmaJet

Read at

comments powered by Disqus